The effect of salbutamol administration by inhalation together with rapid and deep breathing in comparison with the standard method: A clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171231038154N1

Enrollment

110

Registered

2018-08-17

Start date

2018-06-05

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DYSPNEA. Upper respiratory tract hypersensitivity reaction, site unspecified

Interventions

Intervention 1: Intervention group: The patient is asked to breathe rapidly and deeply during medication inhalation. Three puffs are given in rapid succession with 1-second intervals. After 10-15 minu

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients 15–75 years of age who visit the emergency department of Shahid Sadoughi Hospital in Yazd, Iran, due to bronchospasm caused by inhalation, asthma, or COPD. Lack of severe respiratory distress and absence of other underlying diseases that require treatments other than inhaled salbutamol.

Exclusion criteria

Exclusion criteria: Patients who need treatments other than salbutamol, such as atrovent, combivent, or pulmicort; Patients who visit the emergency department with signs of respiratory failure, including acrocyanosis, PO2 below 60 mmHg, or PCO2 above 80 mmHg

Design outcomes

Primary

Measure	Time frame
Peak expiratory flow. Timepoint: 0, 5min, 10min, 15min. Method of measurement: peak flow meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Akbarzadeh

Yazd University of Medical Sciences

dr.akbarzadeh@bums.ac.ir+98 35 3820 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026